Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Tumour treating fields in a combinational therapeutic approach.

Branter J, Basu S, Smith S.

Oncotarget. 2018 Nov 27;9(93):36631-36644. doi: 10.18632/oncotarget.26344. eCollection 2018 Nov 27. Review.

2.

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment.

Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD.

Clin Cancer Res. 2018 Jan 15;24(2):266-275. doi: 10.1158/1078-0432.CCR-17-1117. Epub 2017 Aug 1. Review.

3.

The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.

Burri SH, Gondi V, Brown PD, Mehta MP.

Am J Clin Oncol. 2018 Feb;41(2):191-196. doi: 10.1097/COC.0000000000000395. Review.

4.

Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.

Zhu P, Zhu JJ.

Chin Clin Oncol. 2017 Aug;6(4):41. doi: 10.21037/cco.2017.06.29. Review.

5.

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z.

JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. Erratum in: JAMA. 2018 May 1;319(17):1824.

6.

Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.

Mehta M, Wen P, Nishikawa R, Reardon D, Peters K.

Crit Rev Oncol Hematol. 2017 Mar;111:60-65. doi: 10.1016/j.critrevonc.2017.01.005. Epub 2017 Jan 22. Review.

7.

Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy.

Saria MG, Kesari S.

Clin J Oncol Nurs. 2016 Oct 1;20(5 Suppl):S9-S13. doi: 10.1188/16.CJON.S1.9-13. Review.

8.

Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.

Kesari S, Ram Z; EF-14 Trial Investigators.

CNS Oncol. 2017 Jul;6(3):185-193. doi: 10.2217/cns-2016-0049. Epub 2017 Apr 12.

9.

Tumor treating fields: a new standard treatment for glioblastoma?

Taillibert S, Le Rhun E, Chamberlain MC.

Curr Opin Neurol. 2015 Dec;28(6):659-64. doi: 10.1097/WCO.0000000000000250. Review.

PMID:
26551239
10.

Alternating Electric Fields (TTFields) Activate Cav1.2 Channels in Human Glioblastoma Cells.

Neuhaus E, Zirjacks L, Ganser K, Klumpp L, Schüler U, Zips D, Eckert F, Huber SM.

Cancers (Basel). 2019 Jan 18;11(1). pii: E110. doi: 10.3390/cancers11010110.

11.

Rationale and Background on Tumor-Treating Fields for Glioblastoma.

Schwartz MA, Onuselogu L.

Clin J Oncol Nurs. 2016 Oct 1;20(5 Suppl):S20-4. doi: 10.1188/16.CJON.S1.20-24.

12.

Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields.

Chang E, Pohling C, Beygui N, Patel CB, Rosenberg J, Ha DH, Gambhir SS.

J Neurooncol. 2017 Sep;134(2):259-268. doi: 10.1007/s11060-017-2534-5. Epub 2017 Jul 5.

13.

Tumor treating fields increases membrane permeability in glioblastoma cells.

Chang E, Patel CB, Pohling C, Young C, Song J, Flores TA, Zeng Y, Joubert LM, Arami H, Natarajan A, Sinclair R, Gambhir SS.

Cell Death Discov. 2018 Dec 5;4:113. doi: 10.1038/s41420-018-0130-x. eCollection 2018.

14.

The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.

Turner SG, Gergel T, Wu H, Lacroix M, Toms SA.

World J Surg Oncol. 2014 May 22;12:162. doi: 10.1186/1477-7819-12-162.

15.

Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo.

Giladi M, Weinberg U, Schneiderman RS, Porat Y, Munster M, Voloshin T, Blatt R, Cahal S, Itzhaki A, Onn A, Kirson ED, Palti Y.

Semin Oncol. 2014 Oct;41 Suppl 6:S35-41. doi: 10.1053/j.seminoncol.2014.09.006. Epub 2014 Sep 8.

16.

Alternating Electric Fields Therapy for Malignant Gliomas: From Bench Observation to Clinical Reality.

Wong ET, Lok E, Swanson KD.

Prog Neurol Surg. 2018;32:180-195. doi: 10.1159/000469690. Epub 2018 Jul 10. Review.

PMID:
29990984
17.

Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.

Zhu JJ, Demireva P, Kanner AA, Pannullo S, Mehdorn M, Avgeropoulos N, Salmaggi A, Silvani A, Goldlust S, David C, Benouaich-Amiel A; Zvi Ram on behalf of the EF-14 Trial Investigators.

J Neurooncol. 2017 Dec;135(3):545-552. doi: 10.1007/s11060-017-2601-y. Epub 2017 Aug 28.

18.

Skin toxicities associated with tumor treating fields: case based review.

Lukas RV, Ratermann KL, Wong ET, Villano JL.

J Neurooncol. 2017 Dec;135(3):593-599. doi: 10.1007/s11060-017-2612-8. Epub 2017 Aug 28.

PMID:
28849343
19.

Technological Advances in the Treatment of Cancer: Combining Modalities to Optimize Outcomes.

Wong ET, Toms SA, Ahluwalia MS.

Clin Adv Hematol Oncol. 2015 Nov;13(11 Suppl 11):1-18.

PMID:
26862770
20.

The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.

Clark PA, Gaal JT, Strebe JK, Pasch CA, Deming DA, Kuo JS, Robins HI.

J Clin Neurosci. 2017 Feb;36:120-124. doi: 10.1016/j.jocn.2016.10.042. Epub 2016 Nov 16.

Supplemental Content

Support Center